Showing results (41-50 of 72) with videos related to
Sort By:
Pageof 8
British Journal of Clinical Pharmacology|October 19, 2023
Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysisBehnam Noorani, Rajeev M Menon, Xin Chen, et al.Antiviral Research|January 25, 2011
Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapyEric Lawitz, Eliot Godofsky, Regine Rouzier, et al.Journal of Clinical Pharmacology|May 26, 2011
Pharmacokinetics of oral tonapofylline and its acyl-glucuronide metabolite in patients with mild and moderate hepatic impairmentZhaoyang Li, Liang-Shang Gan, Thomas Marbury, et al.Antimicrobial Agents and Chemotherapy|June 13, 2018
Severe Renal Impairment Has Minimal Impact on Doravirine PharmacokineticsWendy Ankrom, Ka Lai Yee, Rosa I Sanchez, et al.Journal of Clinical Pharmacology|September 29, 2009
Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritisJules I Schwartz, Nancy G B Agrawal, P H Wong, et al.Journal of Clinical Pharmacology|March 10, 2020
The Effect of Renal Impairment on the Pharmacokinetics and Safety of ItacitinibNithya Srinivas, April M Barbour, Noam Epstein, et al.Leukemia & Lymphoma|June 9, 2016
Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment<sup/>Jan de Jong, Donna Skee, Peter Hellemans, et al.Journal of Clinical Pharmacology|February 12, 2016
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of CabozantinibLinh Nguyen, Jaymes Holland, David Ramies, et al.Journal of Clinical Pharmacology|December 28, 2016
Moderate Hepatic Impairment Does Not Affect Doravirine PharmacokineticsSauzanne Khalilieh, Ka Lai Yee, Rachael Liu, et al.Cancer Chemotherapy and Pharmacology|July 2, 2025
Pharmacokinetics, safety, and tolerability of fedratinib in adults with moderate and severe hepatic impairment: results from the phase 1 FEDR-CP-001 trialYizhe Chen, Richard A Preston, Thomas Marbury, et al.Pageof 8